Literature DB >> 32270329

Utility and relevance of modified lateral trapezius myocutaneous flap as a locoregional reconstructive option for medium-sized ablative defects in head and neck cancer-our experience.

Abhishek Singh1, Mudit Agarwal2, Naveen Singh2,3,4, Harit Chaturvedi3, Manikandan Venkatasubramaniyan2, Anshu Chopra4.   

Abstract

PURPOSE: Lateral trapezius myocutaneous (LTMC) flap has been used less frequently for defects pertaining to head and neck cancer ablative surgical defects. This study is to assess the utility of LTMC flap with a new modification of the flap design.
METHODS: This is a retrospective study using LTMC flap with modifications as a reconstructive option for intraoral & extraoral skin defects in head and neck cancer patients following ablative surgery, from August 2014 to October 2019 in a tertiary care hospital. The original technique of LTMC flap was modified for better results and outcomes.
RESULTS: Thirty-five patients underwent lateral trapezius flap reconstruction for ablative defects of oral cavity, laryngopharynx, neck and parotid. Twenty-three patients (65.71%) underwent adjuvant radiation/radiation-chemotherapy while one patient defaulted. Two patients (5.71%) had major flap failure. After the loss of flap in these patients, the operative technique was further modified for better results. However, the disadvantage of using this flap is shoulder disability. Nonetheless in the present study, the disability was reduced after modifying the operating technique by preserving the spinal accessory nerve.
CONCLUSION: The present study demonstrated minimal functional loss, low morbidity with satisfactory results, thus also reducing treatment cost. Thus, LTMC is a reliable reconstructive option in head and neck cancer patients for medium-sized defects.

Entities:  

Keywords:  Head & neck reconstruction; Lateral trapezius myocutaneous flap; Locoregional flap; Shoulder disability

Mesh:

Year:  2020        PMID: 32270329     DOI: 10.1007/s00405-020-05952-6

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  24 in total

1.  Trends of head and neck cancers in urban and rural India.

Authors:  J Kalavathy Elango; P Gangadharan; S Sumithra; M A Kuriakose
Journal:  Asian Pac J Cancer Prev       Date:  2006 Jan-Mar

2.  The folded trapezius flap for through-and-through cheek defects.

Authors:  O M Guillamondegui; B H Campbell
Journal:  Otolaryngol Head Neck Surg       Date:  1987-07       Impact factor: 3.497

3.  The trapezius myocutaneous flap. Dependability and limitations.

Authors:  J L Netterville; W R Panje; M D Maves
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-03

4.  Trapezius myocutaneous flap in reconstructive surgery for head and neck cancer: an original technique.

Authors:  F Demergasso; M V Piazza
Journal:  Am J Surg       Date:  1979-10       Impact factor: 2.565

5.  Use of composite flaps containing bone for major repairs in the head and neck.

Authors:  J Conley
Journal:  Plast Reconstr Surg       Date:  1972-05       Impact factor: 4.730

6.  Myocutaneous trapezius flap.

Authors:  W R Panje
Journal:  Head Neck Surg       Date:  1980 Jan-Feb

7.  The lower trapezius island myocutaneous flap.

Authors:  S M Baek; H F Biller; Y P Krespi; W Lawson
Journal:  Ann Plast Surg       Date:  1980-08       Impact factor: 1.539

Review 8.  Epidemiologic trends in head and neck cancer and aids in diagnosis.

Authors:  Nadarajah Vigneswaran; Michelle D Williams
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2014-05       Impact factor: 2.802

9.  The reliability of pectoralis major myocutaneous flap in head and neck reconstruction.

Authors:  Hamdy H El-Marakby
Journal:  J Egypt Natl Canc Inst       Date:  2006-03

10.  The myocutaneous trapezius flap revisited: a treatment algorithm for optimal surgical outcomes based on 43 flap reconstructions.

Authors:  Anil Can; Dennis P Orgill; J O Dietmar Ulrich; Marc A M Mureau
Journal:  J Plast Reconstr Aesthet Surg       Date:  2014-08-06       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.